Hologic, Inc. (NASDAQ:HOLX) Receives Consensus Rating of “Hold” from Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX) have received an average recommendation of “Hold” from the fifteen brokerages that are currently covering the stock, MarketBeat.com reports. Thirteen research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $78.4167.

Several analysts recently weighed in on HOLX shares. Evercore downgraded Hologic from an “outperform” rating to an “in-line” rating and decreased their price objective for the company from $79.00 to $78.00 in a report on Monday, January 5th. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th.

Hedge Funds Weigh In On Hologic

A number of large investors have recently bought and sold shares of the business. Winnow Wealth LLC purchased a new position in shares of Hologic in the 3rd quarter valued at $26,000. Root Financial Partners LLC bought a new position in shares of Hologic in the 3rd quarter worth $27,000. Harbor Capital Advisors Inc. purchased a new stake in shares of Hologic during the 4th quarter worth $27,000. SJS Investment Consulting Inc. lifted its stake in shares of Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 362 shares during the last quarter. Finally, Loomis Sayles & Co. L P bought a new stake in Hologic during the second quarter valued at about $33,000. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 0.1%

HOLX opened at $75.41 on Tuesday. The stock’s fifty day moving average is $75.16 and its two-hundred day moving average is $72.97. The company has a market capitalization of $16.83 billion, a P/E ratio of 31.42, a PEG ratio of 2.24 and a beta of 0.73. Hologic has a 52 week low of $51.90 and a 52 week high of $75.75. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the firm earned $0.87 earnings per share. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. Analysts forecast that Hologic will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.